Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY (CAPACITY-COVID)
Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in COVID-19 patients. By collecting this information in a standardized manner, CAPACITY can aid in providing more insight in (1) the incidence of cardiovascular complications in patients with COVID-19, and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease.
The CAPACITY extension to the ISARIC-WHO CRF consists of additional data collection instruments for:
- cardiac history and cardiovascular risk factors
- prior use of cardiac medication or NSAIDs
- electrocardiography (ECG)
- echocardiography
- cardiac MRI
- invasive cardiac procedures
- cardiac complications
- cardiac biomarkers
- cardiac outcome during admission
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Folkert W. Asselbergs, MD, PhD
- Phone Number: +31 (0) 88 755 5555
- Email: f.w.asselbergs@umcutrecht.nl
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- Recruiting
- University Medical Center Utrecht
-
Contact:
- Marijke Linschoten, MD
- Phone Number: +31 (0)88 755 5555
- Email: m.p.m.linschoten@umcutrecht.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Highly suspected/confirmed infection with SARS-CoV-2
Exclusion Criteria:
- Patients that opt-out
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of cardiovascular complications in patients with COVID-19
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-161/C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.